Stock listing
NASDAQ:GPCR Structure Therapeutics, Inc. Stock
Follow Structure Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:GPCR
$16.13 USD -1.23 (-7.1%)
Close on Nov 20, 2026
- Day range
- $16.08 – $17.08 USDNov 20, 2026
- Volume
- 786,126 sharesNov 20, 2026
- Market cap
- $1.15B USDAt the close on Nov 20, 2026 · price × 71.31M shares outstanding
- 52-week range
- $16.08 – $94.90 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $36.08M USDMedian day 1.06M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GPCR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $16.13 | -1.23 | -7.1% | $16.73 | $17.08 | $16.08 | 786,126 | |
| $17.36 | -0.81 | -4.5% | $18.16 | $18.57 | $17.34 | 1,100,378 | |
| $18.17 | -0.40 | -2.2% | $18.53 | $18.69 | $17.81 | 583,625 | |
| $18.57 | -1.43 | -7.1% | $19.82 | $19.99 | $18.38 | 761,993 | |
| $20.00 | +0.16 | +0.8% | $19.89 | $20.50 | $19.09 | 1,345,855 | |
| $19.84 | -1.11 | -5.3% | $20.50 | $21.00 | $19.62 | 1,037,288 | |
| $20.95 | -0.78 | -3.6% | $21.79 | $21.99 | $20.78 | 1,001,659 | |
| $21.73 | +0.32 | +1.5% | $21.41 | $22.72 | $21.02 | 1,443,668 | |
| $21.41 | +1.06 | +5.2% | $20.57 | $22.13 | $20.57 | 1,235,540 | |
| $20.35 | +1.27 | +6.7% | $19.44 | $21.31 | $18.70 | 1,615,812 | |
| $19.08 | -1.28 | -6.3% | $20.47 | $20.56 | $18.76 | 1,011,097 | |
| $20.36 | +0.01 | 0.0% | $20.69 | $21.48 | $19.94 | 738,485 | |
| $20.35 | -0.12 | -0.6% | $20.70 | $21.16 | $20.30 | 612,850 | |
| $20.47 | -1.40 | -6.4% | $22.05 | $22.05 | $20.42 | 788,016 | |
| $21.87 | -0.07 | -0.3% | $21.59 | $22.36 | $21.07 | 695,900 | |
| $21.94 | +0.46 | +2.1% | $21.51 | $22.16 | $21.39 | 929,400 | |
| $21.48 | -0.07 | -0.3% | $21.29 | $21.67 | $20.50 | 987,400 | |
| $21.55 | +0.45 | +2.1% | $21.15 | $22.08 | $20.90 | 731,600 | |
| $21.10 | -0.09 | -0.4% | $21.16 | $21.98 | $21.05 | 685,900 | |
| $21.19 | -0.74 | -3.4% | $21.79 | $21.97 | $21.13 | 796,800 | |
| $21.93 | -0.08 | -0.4% | $21.72 | $22.55 | $21.72 | 701,300 | |
| $22.01 | -0.87 | -3.8% | $23.00 | $23.32 | $21.77 | 804,400 | |
| $22.88 | +0.87 | +4.0% | $22.11 | $23.83 | $22.11 | 1,408,600 | |
| $22.01 | +0.93 | +4.4% | $21.08 | $22.25 | $20.74 | 1,312,600 | |
| $21.08 | -1.11 | -5.0% | $22.15 | $22.21 | $20.73 | 1,160,800 | |
| $22.19 | +0.31 | +1.4% | $21.89 | $22.62 | $21.81 | 1,411,000 | |
| $21.88 | -0.43 | -1.9% | $22.46 | $22.89 | $21.55 | 2,068,200 | |
| $22.31 | -1.60 | -6.7% | $23.92 | $24.03 | $22.10 | 1,434,800 | |
| $23.91 | -1.63 | -6.4% | $25.25 | $25.50 | $23.89 | 1,660,300 | |
| $25.54 | -0.13 | -0.5% | $25.73 | $26.15 | $25.29 | 592,800 | |
| $25.67 | -1.01 | -3.8% | $26.57 | $26.80 | $25.09 | 939,200 | |
| $26.68 | -0.79 | -2.9% | $27.14 | $28.05 | $26.38 | 1,048,800 | |
| $27.47 | -0.12 | -0.4% | $27.55 | $27.85 | $26.69 | 1,421,500 | |
| $27.59 | -0.08 | -0.3% | $28.10 | $28.21 | $26.41 | 1,867,800 | |
| $27.67 | -1.31 | -4.5% | $28.99 | $29.25 | $27.57 | 1,713,500 | |
| $28.98 | -2.29 | -7.3% | $31.27 | $31.39 | $28.93 | 2,591,700 | |
| $31.27 | -1.42 | -4.3% | $33.05 | $33.05 | $31.08 | 2,197,000 | |
| $32.69 | -2.375 | -6.8% | $34.78 | $34.93 | $32.44 | 1,726,400 | |
| $35.07 | -0.865 | -2.4% | $34.86 | $35.64 | $34.43 | 1,282,600 | |
| $35.93 | -0.09 | -0.2% | $36.29 | $37.20 | $35.50 | 1,587,800 | |
| $36.02 | +0.07 | +0.2% | $35.35 | $36.27 | $34.43 | 2,110,900 | |
| $35.95 | -0.96 | -2.6% | $36.50 | $37.30 | $34.96 | 1,400,500 | |
| $36.91 | +0.10 | +0.3% | $36.99 | $37.74 | $36.25 | 611,200 | |
| $36.81 | +1.81 | +5.2% | $35.34 | $36.99 | $35.00 | 1,021,500 | |
| $35.00 | -0.10 | -0.3% | $35.04 | $35.63 | $34.42 | 1,546,900 | |
| $35.10 | -0.40 | -1.1% | $36.05 | $36.45 | $35.05 | 1,178,200 | |
| $35.50 | -3.45 | -8.9% | $39.19 | $39.19 | $35.42 | 1,648,900 | |
| $38.95 | +0.51 | +1.3% | $38.36 | $39.03 | $37.75 | 1,466,100 | |
| $38.44 | -0.22 | -0.6% | $38.92 | $39.24 | $37.82 | 1,498,300 | |
| $38.66 | -0.89 | -2.3% | $39.82 | $40.27 | $38.10 | 1,276,100 | |
| $39.55 | -1.68 | -4.1% | $40.51 | $40.90 | $39.29 | 761,400 | |
| $41.23 | +0.85 | +2.1% | $41.23 | $44.94 | $40.49 | 1,562,300 | |
| $40.38 | -6.96 | -14.7% | $46.84 | $47.38 | $40.26 | 3,409,900 | |
| $47.34 | 0.00 | 0.0% | $47.26 | $48.06 | $46.73 | 281,700 | |
| $47.34 | -0.46 | -1.0% | $48.21 | $48.25 | $46.37 | 621,400 | |
| $47.80 | +0.67 | +1.4% | $47.76 | $48.64 | $46.07 | 1,064,600 | |
| $47.13 | +1.22 | +2.7% | $46.02 | $48.03 | $45.58 | 815,700 | |
| $45.91 | -1.46 | -3.1% | $47.08 | $47.38 | $45.10 | 1,394,300 | |
| $47.37 | -1.85 | -3.8% | $48.93 | $49.20 | $46.96 | 601,700 | |
| $49.22 | -0.13 | -0.3% | $49.61 | $49.81 | $48.50 | 318,900 | |
| $49.35 | -0.57 | -1.1% | $49.75 | $50.07 | $48.45 | 937,200 | |
| $49.92 | +0.91 | +1.9% | $49.65 | $51.02 | $49.37 | 463,890 | |
| $49.01 | -0.08 | -0.2% | $48.61 | $49.33 | $47.62 | 822,246 | |
| $49.09 | -1.43 | -2.8% | $50.70 | $51.11 | $49.01 | 592,500 | |
| $50.52 | -3.61 | -6.7% | $54.15 | $54.60 | $50.33 | 1,429,100 |
- Ticker
- NASDAQ:GPCR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 4, 2026
Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
Latest deck · Sep 8, 2026
Corporate Update (September 2026)
Corporate update · 35 slides
Latest news
Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
Nov 4, 2026
Closed $20.36 (0.0%) on Nov 4, 2026
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
Oct 19, 2026
Closed $22.88 (+4.0%) on Oct 20, 2026
Structure Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 2 in the last 12 months · 2 in all · newest Nov 4, 2026 · oldest 2026
- Decks
- 7 decks · latest Sep 8, 2026
Valuation
Price/book 0.9× against a median of 4.2×: the lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$82.92M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.38
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Structure Therapeutics, Inc. · NASDAQ:GPCR | US$1.15B | −US$82.92M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.38 |
| GH Research PLC · NASDAQ:GHRS | US$1.20B | US$841.0M | n/a | n/a | n/a | 3.4× | n/a | 0.0× | 1.28 |
| Vor Biopharma Inc. · NASDAQ:VOR | US$1.18B | US$697.4M | 0.9× | n/a | n/a | n/a | n/a | n/a | 1.25 |
| Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A · SZSE:300204 | US$1.17B | US$1.01B | n/a | 36.1× | n/a | 3.9× | −53.3% | 0.0× | n/a |
| OPKO Health, Inc. · NASDAQ:OPK | US$1.17B | US$1.26B | n/a | 2.5× | n/a | 1.0× | −29.5% | 0.4× | 0.90 |
| D&D Pharmatech Co., Ltd. · KRX:347850 | US$1.16B | US$1.13B | n/a | 549× | n/a | 11.5× | −785.5% | 0.8× | n/a |
| CStone Pharmaceuticals · HKEX:2616 | US$1.16B | US$974.9M | n/a | 24.1× | n/a | 6.0× | −162.1% | 0.3× | n/a |
| COMPASS Pathways Plc · NASDAQ:CMPS | US$1.14B | US$747.8M | n/a | n/a | n/a | 8.0× | n/a | 0.4× | 1.65 |
| Ascentage Pharma Group International · HKEX:6855 | US$1.11B | US$1.14B | n/a | 13.7× | n/a | 13.4× | −216.5% | 3.8× | n/a |
| Shenzhen Chipscreen Biosciences Co. Ltd. Class A · SSE:688321 | US$1.10B | US$1.10B | 102× | 6.8× | n/a | 2.9× | 6.6% | 0.5× | n/a |
| Pharma Mar SA · BME:PHM | US$1.10B | US$978.5M | 14.6× | 3.8× | 16.6× | 4.2× | 28.8% | 0.3× | n/a |
| Median of the others | US$1.16B | US$993.9M | 14.6× | 13.7× | 16.6× | 4.2× | −53.3% | 0.4× | 1.27 |
Forecasts
11 strong buy · 4 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 104.31 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.20 · 4 analysts
Team and board
| Officer | Role |
|---|---|
| Jun Yoon | Chief Financial Officer |
Events
- Next results
- Feb 25, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · After close | +1.5% |
| Q2 2026 | Aug 6, 2026 · After close | +1.0% |
| Q1 2026 | May 7, 2026 · After close | −0.1% |
| Q4 2025 | Feb 26, 2026 | −5.3% |
| Q3 2025 | Nov 6, 2025 · After close | −1.9% |
| Q2 2025 | Aug 6, 2025 · After close | −0.7% |
| Q1 2025 | May 8, 2025 · After close | −4.7% |
| Q4 2024 | Feb 27, 2025 | +19.5% |
| Q3 2024 | Nov 13, 2024 · After close | +3.6% |
| Q2 2024 | Aug 8, 2024 · After close | −2.1% |
All 16 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −7.3% |
| Q4 2023 | Mar 8, 2024 · Before open | +2.4% |
| Q3 2023 | Nov 14, 2023 · After close | −9.8% |
| Q2 2023 | Aug 10, 2023 · After close | −6.1% |
| Q1 2023 | May 11, 2023 · After close | +5.6% |
| Q4 2022 | Mar 31, 2023 · After close | +9.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (September 2026) | Corporate update | 35 slides | Sep 8, 2026 |
| Investor Presentation (June 2026) | Investor deck | 21 slides | June 2026 |
| Corporate Update (March 2026) | Corporate update | 35 slides | Mar 16, 2026 |
| Technical Presentation (December 2025) | Technical | 47 slides | Dec 8, 2025 |
| Corporate Update (June 2024) | Corporate update | 31 slides | Jun 3, 2024 |
| Corporate Update (December 2023) | Corporate update | 35 slides | Dec 18, 2023 |
| Corporate Update (September 2023) | Corporate update | 24 slides | Sep 29, 2023 |
IPO
Priced at US$15.00 an ADS on Feb 2, 2023.
- Price
- US$15.00 an ADS
- ADSs offered
- 10,740,000 American depositary shares
- Offering size
- US$161.1 million
- Underwriters' option
- Up to 1,611,000 more ADSs
- Listing
- GPCR on the Nasdaq Global Market
- Underwriters
- Jefferies, SVB Securities, Guggenheim Securities, BMO Capital Markets · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 14, 2022 |
| Filed publicly | Jan 12, 2023 |
| Amended once | Jan 30, 2023 |
| Shares registered with an exchange | Jan 30, 2023 |
| Declared effective by the SEC | Feb 2, 2023 |
| Final prospectus, with the price | Feb 6, 2023 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 6, 2023 |
| EFFECT · Notice that a registration is effective | Feb 2, 2023 |
| S-1MEF · Registration of more shares for the same offering | Feb 2, 2023 |
| CERT · Exchange's certificate of listing | Feb 2, 2023 |
| CORRESP · Letter to the SEC | Jan 31, 2023 |
| CORRESP · Letter to the SEC | Jan 31, 2023 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 30, 2023 |
| S-1/A · Registration statement, amended | Jan 30, 2023 |
| CORRESP · Letter to the SEC | Jan 23, 2023 |
| CORRESP · Letter to the SEC | Jan 12, 2023 |
All 19 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Jan 12, 2023 |
| UPLOAD · Letter from the SEC | Jan 4, 2023 |
| DRS/A · Draft registration statement, amended | Dec 6, 2022 |
| DRSLTR · Letter to the SEC with a draft | Dec 5, 2022 |
| UPLOAD · Letter from the SEC | May 27, 2022 |
| DRS/A · Draft registration statement, amended | May 13, 2022 |
| DRSLTR · Letter to the SEC with a draft | May 12, 2022 |
| UPLOAD · Letter from the SEC | Mar 14, 2022 |
| DRS · Draft registration statement | Feb 14, 2022 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 6, 2023
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 3.90M | 2.60M | 949.2K | 623.3K | 266.4K | 20.0K |
| Gross profit | -3.90M | -2.60M | -949.2K | -623.3K | -266.4K | -20.0K |
| Research and development | 225.3M | 108.8M | 70.1M | 36.2M | 29.1M | 12.4K |
| Selling, general and administrative | 61.6M | 49.4M | 32.7M | 16.4M | 8.59M | 3.54K |
| Operating income | -176.6M | -158.2M | -102.8M | -52.6M | -37.7M | -15.9K |
| Depreciation and amortization | 1.33M | 992.0K | 295.0K | 277.0K | 72.0K | 20.0K |
| EBITDA | -175.2M | -157.2M | -102.5M | -52.3M | -37.6M | 4.13K |
| Interest expense | 13.4M | 1.53M | 122.2K | 5 | ||
| Income before tax | -140.7M | -122.2M | -89.4M | -51.3M | -37.8M | -15.7K |
| Income tax | 515.0K | 310.0K | 236.0K | 17.0K | 231.0K | 138 |
| Net income | -141.2M | -122.5M | -89.6M | -51.3M | -40.0M | -15.9K |
| Earnings per share, basic | -0.80 | -0.78 | -0.81 | -5.51 | -1.09 | -0.00 |
| Earnings per share, diluted | -0.80 | -0.78 | -0.81 | -5.51 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 799.6M | 169.5M | 129.8M | 26.1M | 105.3M | 16.4M |
| Short-term investments | 646.6M | 714.0M | 337.5M | 64.8M | 2.00M | 21.1M |
| Current assets | 1.57B | 891.2M | 473.6M | 93.1M | 109.3M | 38.4M |
| Property, plant and equipment | 6.65M | 3.48M | 3.23M | 1.03M | 1.79M | 277.0K |
| Total assets | 1.58B | 903.3M | 482.0M | 97.8M | 111.2M | 38.7M |
| Accounts payable | 13.9M | 8.02M | 4.74M | 6.01M | 3.48M | 1.53M |
| Current liabilities | 63.3M | 36.0M | 24.7M | 13.0M | 8.66M | 3.04M |
| Total debt | 6.49M | 3.86M | 5.45M | 260.0K | 621.0K | 280.0K |
| Total liabilities | 67.5M | 38.5M | 29.1M | 13.0M | 175.9M | 61.2M |
| Shareholders' equity | 1.52B | 864.8M | 453.0M | -115.1M | -64.7M | -22.5M |
| Shares outstanding | 212.5M | 171.9M | 139.2M | 10.5M | 36.6M | 36.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -222.2M | -116.6M | -79.5M | -46.1M | -32.2M | -14.3M |
| Capital spending | -3.61M | -1.29M | -2.17M | -155.0K | -1.21M | -19.0K |
| Free cash flow | -225.8M | -117.9M | -81.7M | -46.3M | -33.4M | -14.3M |
| Cash from investing | 89.8M | -358.9M | -268.3M | -62.1M | 17.9M | -21.1M |
| Cash from financing | 762.5M | 515.3M | 451.5M | 29.0M | 103.3M | 25.8M |
| Share buybacks | -6.00K | |||||
| Change in cash | 630.1M | 39.7M | 103.7M | -79.2M | 89.0M | -9.59M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 21, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 7, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 424B5 · Prospectus | May 7, 2026 | Offer document | SEC |
| ARS · Annual report to shareholders | Apr 23, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 23, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 15, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 16, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 26, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 5, 2026 | Material contract | SEC |
| 8-K · Current report | Dec 10, 2025 | Current report | SEC |
| 424B5 · Prospectus | Dec 10, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Dec 8, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 8, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| S-3ASR · Registration statement | Aug 6, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 25, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 24, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 24, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 10, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 17, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 17, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Aug 28, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 28, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 27, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 8-K · Current report | Jun 27, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 10, 2024 | Other filings | SEC |
| 424B4 · Prospectus | Jun 6, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 6, 2024 | Other filings | SEC |
| S-1MEF · Registration of more shares for the same offering | Jun 5, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Jun 4, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 3, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 3, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 3, 2024 | Current report | SEC |
| 144 · Notice of proposed sale | Jun 3, 2024 | Other filings | SEC |
| S-1 · Registration statement | Jun 3, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 3, 2024 | Current report | SEC |
| CORRESP · Letter to the SEC | May 31, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 31, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | May 30, 2024 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | May 24, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 22, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 25, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 25, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 19, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 20, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 20, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 20, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 20, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 8, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 8, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 8, 2024 | Results | SEC |
| 4 · Change in ownership | Feb 15, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 8, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 6, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 27, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Dec 20, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Dec 18, 2023 | Current report | SEC |
| 4 · Change in ownership | Dec 7, 2023 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Nov 30, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 27, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 24, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 24, 2023 | Other filings | SEC |
| DRS · Draft registration statement | Nov 20, 2023 | Offer document | SEC |
| S-1 · Registration statement | Nov 17, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 17, 2023 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Nov 17, 2023 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Nov 16, 2023 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Nov 14, 2023 | Explanation request | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
This page holds 200 of 275 filings. Open Filings
Cap table
Built by 6ix from Structure Therapeutics, Inc.’s releases
- Common shares
- 71,309,857
- Fully diluted
- 71,309,857
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 71,309,857 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 71,309,857 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ted W Love Other companies: Lisata Therapeutics, Inc. (Director · Since at least Sep 17, 2026); Jazz Pharmaceuticals plc (Director · Since at least Dec 1, 2025); Gilead Sciences, Inc. (Director · Since at least Feb 1, 2024); Royalty Pharma plc (Director · Since at least Jul 30, 2020); Seagen Inc (Director · Aug 16, 2020 – Dec 14, 2023 · Past); Portola Pharmaceuticals Inc (Director · Sep 18, 2019 – Jul 2, 2020 · Past); Global Blood Therapeutics Inc (President and CEO, Director · Aug 11, 2015 – Oct 5, 2022 · Past); Cascadian Therapeutics Inc (Director · Sep 5, 2013 – Mar 9, 2018 · Past); Savara, Inc. (Director · Sep 5, 2012 – Jun 19, 2013 · Past); Humanigen Inc (Director · Aug 10, 2012 – Jul 10, 2015 · Past); Amicus Therapeutics Inc (Director · Jun 13, 2012 – Jun 4, 2020 · Past); Bio-Rad Laboratories, Inc. (Director · Mar 24, 2010 – Mar 24, 2010 · Past); Onyx Pharmaceuticals Inc (EVP, R&D and Tech. Operations · Feb 1, 2010 – Jul 25, 2012 · Past); Affymax Inc (Director · Dec 14, 2006 – Jun 13, 2012 · Past); Santarus Inc (Director · Jun 7, 2006 – Jan 2, 2014 · Past); Oruka Therapeutics, Inc. (Director · Mar 7, 2006 – Feb 5, 2010 · Past) | Director · Since at least Aug 3, 2023 |
| Daniel G. Welch Other companies: Prothena Corporation plc (Chair of the Board · Since at least Feb 21, 2024); Ultragenyx Pharmaceutical Inc. (Director · Since at least Apr 8, 2015); Nuvation Bio Inc. (Director · Feb 10, 2021 – May 24, 2024 · Past); AveXis Inc (Director · Feb 10, 2016 – May 15, 2018 · Past); Intercept Pharmaceuticals Inc (Director · Nov 24, 2015 – May 28, 2020 · Past); Corium International Inc (Director · Apr 2, 2014 – Apr 2, 2014 · Past); Hyperion Therapeutics Inc (Director · Aug 23, 2012 – May 7, 2015 · Past); Seagen Inc (Director · Jun 13, 2007 – Dec 14, 2023 · Past); InterMune Inc (Chairman, CEO and President, Director · Mar 15, 2006 – Sep 29, 2014 · Past) | Director · Since at least Feb 2, 2023 |
| Angus C. Russell Other companies: Lineage Cell Therapeutics, Inc. (Director · Since at least Dec 12, 2014); TherapeuticsMD, Inc. (Director · Mar 18, 2015 – Sep 29, 2022 · Past); Mallinckrodt Inc (Director · Aug 14, 2014 – Jun 16, 2022 · Past); Revance Therapeutics, Inc. (Director · Mar 4, 2014 – Feb 4, 2025 · Past); Questcor Pharmaceuticals Inc (Director · Jun 8, 2013 – Aug 14, 2014 · Past); InterMune Inc (Director · Oct 31, 2011 – Sep 29, 2014 · Past) | Director · Since at least Aug 26, 2024 |
| Eric Dobmeier Other companies: Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Janux Therapeutics, Inc. (Director · Since at least Jul 19, 2024); Aduro Biotech Inc (President, CEO, Director · Oct 5, 2020 – Aug 11, 2023 · Past); Atara Biotherapeutics, Inc. (Director · Jun 27, 2019 – Nov 10, 2023 · Past); Adaptive Biotechnologies Corporation (Director · Jun 26, 2019 – Feb 14, 2021 · Past) | Director · Since at least Feb 2, 2023 |
| Matthew Lang Other companies: Metsera, Inc. (CHIEF LEGAL OFFICER · Since at least Apr 28, 2025); Lyell Immunopharma, Inc. (Chief Business Officer · Jul 1, 2023 – Feb 10, 2025 · Past); Myovant Sciences Ltd (General Counsel & Corp. Secy. · Apr 5, 2019 – Mar 10, 2023 · Past) | COO & GC · Since at least Apr 15, 2026 |
| Ashley Hall Other companies: OnKure Therapeutics, Inc. (Chief Development Officer · Oct 11, 2020 – Aug 28, 2023 · Past); Esperion Therapeutics, Inc. (Chief Development Officer · Feb 26, 2020 – Jan 28, 2021 · Past) | Chief Development Officer · Since at least Sep 18, 2024 |
| Ramy Farid Other companies: Vir Biotechnology, Inc. (Director · Since at least May 29, 2024); Schrodinger, Inc. (President and CEO, Board Member · Since at least Feb 5, 2020) | Director · Feb 2, 2023 – Feb 7, 2023 · Past |
| Joanne Waldstreicher Other companies: Becton, Dickinson and Company (Director · Since at least Jul 24, 2023) | Director · Since at least Feb 2, 2023 |
| Melita Sun Jung Other companies: Terns Pharmaceuticals, Inc. (Chief Business Officer · Apr 22, 2024 – Jan 30, 2025 · Past) | Chief Business Officer · Feb 2, 2023 – Feb 7, 2023 · Past |
| Raymond C Stevens Other companies: Danaher Corporation (Director · Since at least Feb 21, 2017) | CHIEF EXECUTIVE OFFICER, Director · Since at least Feb 2, 2023 |
All 15 people
| Person | Seat |
|---|---|
| Crespo Blas Coll | CHIEF MEDICAL OFFICER · Since at least Sep 18, 2024 |
| John Joseph Berrios | Chief Commercial Officer · Since at least Aug 6, 2026 |
| Jun Yoon | Chief Financial Officer · Since at least Feb 2, 2023 |
| Mark Allen Bach | CHIEF MEDICAL OFFICER · Feb 2, 2023 – Mar 15, 2024 · Past |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER · Since at least Feb 2, 2023 |
Log in to ask 6ix AI your own questions about Structure Therapeutics, Inc.